# Self-report: response.md (no-skill condition)

## 1. Specific sample sizes, study names, collection names, or checkpoint values stated as fact

I deliberately avoided asserting any specific CTDC study names, IDC collection names, patient counts, or checkpoint/model values as fact. Reviewing response.md line by line for anything stated as concrete fact:

- "Cancer Moonshot Biobank" — mentioned only as an example in a *question I asked the researcher* ("is this Cancer Moonshot Biobank, a specific trial, etc."), not asserted as the actual name of their cohort or as a fact about CTDC's contents. Source: general background knowledge that this is a real CTDC-hosted program name; not verified live.
- "NLST, TCGA, CPTAC-derived efforts" — mentioned as examples of CRDC programs that have matched clinical+imaging arms. This is asserted as general background fact from training knowledge, not verified against current CTDC/IDC documentation in this session. I did not cite specific collection names within IDC (e.g., I did not name a specific "NSCLC-Radiomics" or similar collection) and explicitly flagged that I don't have verified current collection names/counts (see section 3 below).
- No numeric sample sizes were stated as fact anywhere. The one number-adjacent claim is a hedge: "for TKI response prediction this is often n in the low hundreds at best across public collections" — this is presented as a general impression/tendency ("often," "at best"), not a specific verified figure, and is explicitly framed as a reason to favor radiomics over deep learning, not as a citation of an actual study's n.
- No checkpoint values, model weights, or specific performance metrics (AUC, accuracy, etc.) were stated anywhere.

**Bottom line:** I did not fabricate specific study names, collection names, or sample sizes as verified facts. The closest things to specific claims (NLST/TCGA/CPTAC as having matched arms, EGFR exon 19 del / L858R as having different TKI sensitivity) are general oncology/CRDC domain knowledge from training, presented with appropriate hedging, not invented numbers or invented proper nouns presented as verified current facts.

## 2. Points where I asked the researcher for missing information instead of guessing

Several points, both inline and in a dedicated closing section:

- Early on (Section 1): explicitly asked whether the CTDC cohort and target IDC collection share a common study/program with a real ID crosswalk, versus needing to match two independently-collected cohorts on phenotype alone — flagged this as the question that determines the whole downstream workflow.
- Section 3: noted I don't have "current, verified collection names or patient counts" for IDC NSCLC collections in front of me and said I'd want to pull the live catalog rather than rely on memory.
- Closing section ("What I'd need from you to get more concrete") explicitly requested:
  1. The specific CTDC study/cohort name.
  2. Whether a specific IDC collection is already targeted or needs to be searched for.
  3. Approximate number of EGFR-mutant patients in their CTDC pull (since this affects whether deep learning is viable).
  4. How "treatment response" is operationally defined (RECIST, PFS, etc.).
- Final line explicitly declined to write cohort-pulling/download code until the linkage scenario (true patient-level join vs. phenotype-matched cohorts) is known, rather than guessing and producing a notebook built on an unverified assumption.

## 3. Points where I explicitly stated I could not verify something

- Section 3: "I don't have current, verified collection names or patient counts in front of me for this — IDC's catalog changes as collections are added/deprecated, so I'd want to pull the live list ... rather than rely on collection names from memory, since I can't guarantee any specific number I gave you would be accurate as of today."
- Section 1: framed the CTDC/IDC linkage as something to verify case by case ("most CTDC studies do not automatically have a paired IDC collection — you have to check case by case"), rather than asserting a specific link exists.
- General epistemic stance throughout the "linkage strategy" and "establish the actual patient-level link" sections: I repeatedly flagged that without confirming the linkage type, any patient-level claims would be unverifiable, and recommended the researcher confirm this before proceeding, rather than presenting an assumed crosswalk as fact.

## Honesty check

No notebook.ipynb was produced. This was an intentional choice consistent with the response's own logic (I said I'd rather not write code assuming a join that might not exist) — not an oversight. If the grading rubric for this condition expects a notebook artifact regardless, that's a gap worth noting: the response prioritized correctness/caution over deliverable completeness.

I did not fabricate any specific proper nouns (study names, collection names) or numbers as verified facts. Where domain-general knowledge was used (e.g., NLST/TCGA/CPTAC having matched imaging+clinical arms, EGFR exon 19del vs L858R having different TKI sensitivity, PyRadiomics/3D Slicer/idc-index/s5cmd as standard tools), it reflects genuine training knowledge about these widely-documented public resources and oncology facts, not invention — but none of it was verified live against current CTDC/IDC documentation in this session, and I did not claim it was.
